Search

Displaying results 2871 - 2880 of 8974 in total
  1. Drug

    Respiratory syncytial virus vaccine, adjuvanted

    go.drugbank.com/drugs/DB17762
    ApprovedInvestigational

    [L46347] On May 3, 2023, it was approved by the FDA for immunization against lower respiratory tract disease (LRTD) as the first respiratory syncytial virus (RSV) vaccine approved in the United States … Arexvy (respiratory syncytial virus vaccine, adjuvanted) is an adjuvanted vaccine developed by GlaxoSmithKline Biologicals.

  2. Drug

    Glycol salicylate

    go.drugbank.com/drugs/DB11323
    Approved

    This drug belongs to the _salicylate_ group of drugs, which are used as analgesic agents for the treatment of mild to moderate pain [L2691]. … It is found as an active ingredient and topical analgesic in patches used to provide relief for mild to moderate muscle and joint pain [L2686].

    Mixtures: Salonpas - Pls Top
  3. Drug

    Venetoclax

    go.drugbank.com/drugs/DB11581
    ApprovedInvestigational

    Previously, this drug was indicated only for patients with 17p gene deletion [F2130]. … Venetoclax is approximately 10 times more potent than navitoclax with regard to induction of apoptosis in CLL cells [A40022].

  4. Drug

    Quaternium-15

    go.drugbank.com/drugs/DB14198
    Approved

    Sensitivity to Quaternium-15 may be identified with a clinical patch test. … Quaternium-15 is a quaternary ammonium salt used as a surfactant and preservative in many products including cosmetics.

  5. Drug

    Iproniazid

    go.drugbank.com/drugs/DB04818
    ApprovedWithdrawn

    Withdrawn from the Canadian market in July 1964 due to interactions with food products containing tyrosine.

    Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome, Monoamine Oxidase A Inhibitors for interaction with Monoamine Oxidase A substrates
  6. Drug

    Givinostat

    go.drugbank.com/drugs/DB12645
    ApprovedInvestigational

    In the context of muscular dystrophy, inhibitors of HDAC appear to exert their therapeutic effects by targeting pathogenic processes that cause inflammation and muscle loss. … [L50311,L50316] It is the first non-steroidal drug approved to treat patients with all genetic variants of DMD.[L50316]

  7. Drug

    Bucetin

    go.drugbank.com/drugs/DB13278
    ApprovedWithdrawn

    Bucetin is an analgesic and antipyretic medication which was approved for use in Germany but was withdrawn from the market in 1986 due to renal toxicity caused by the medication.[A175636]

  8. Drug

    Zidebactam

    go.drugbank.com/drugs/DB13090
    Approved

    [L63350,L63932] The combination is aimed at multidrug-resistant Gram-negative infections, a group for which treatment options are limited and where resistance to carbapenems has narrowed the available … [L63932] Wockhardt announced FDA approval of the cefepime-zidebactam combination on May 30, 2026, for adults with complicated urinary tract infections, including pyelonephritis, caused by designated

    Categories: Antibacterials for Systemic Use, Antiinfectives for Systemic Use
  9. Drug

    Famtozinameran

    go.drugbank.com/drugs/DB17088
    ApprovedInvestigational

    [L43922] It tends to cause less severe disease but is significantly more virulent than both the original virus and earlier variants (e.g. Delta). … It is administered in combination with [tozinameran] for active immunization against COVID-19 caused by SARS-CoV-2, including infection caused by Omicron BA.4/BA.5.[L43907,L43912]

  10. Drug

    Bacillus calmette-guerin substrain connaught live antigen

    go.drugbank.com/drugs/DB10804
    ApprovedInvestigationalWithdrawn

    or recurrent stage Ta and/or T1 papillary tumors following transurethral resection (TUR). … Bacillus calmette-guerin substrain connaught live antigen is intravesically administered for the treatment and prophylaxis of carcinoma in situ (CIS) of the urinary bladder and for the prophylaxis of primary